# A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients

> **NCT00002248** · PHASE1 · COMPLETED · sponsor: **Univax Biologics Inc** · enrollment: 40 (—)

## Conditions studied

- Cryptosporidiosis
- HIV Infections

## Interventions

- **DRUG:** Cryptosporidium Immune Whey Protein Concentrate (Bovine)

## Key facts

- **NCT ID:** NCT00002248
- **Lead sponsor:** Univax Biologics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 40 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002248, "A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00002248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*